Co-Diagnostics and DNA Logix Form Joint Venture to Address High Burden Developing Countries

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SALT LAKE CITY--(BUSINESS WIRE)--Co-Diagnostics, Inc. and DNA Logix announced today that they have reached an agreement to form a joint venture, Co-Diagnostics HBDC LLC, to address diagnostic problems for infectious diseases unique to high burden developing countries (HBDC). It is estimated that while HBDC’s have 90% of the burden of disease worldwide, only about 10% of research and development is devoted to them. Co-Diagnostics HBDC will sell testing products and services to these middle- and low-income countries based on proprietary real-time PCR testing technology developed by DNA Logix and licensed to Co-Diagnostics HBDC specifically for that market.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC